Patricio E. Massera
Chief Executive Officer at MOLMED S.P.A.
Profile
Patricio E.
Massera is currently the Chief Executive Officer & Executive Director at AGC Biologics SpA.
He also holds the position of Chief Executive Officer at AGC Biologics A since 2019 and at AGC Biologics, Inc. since 2012.
In terms of education, Mr. Massera completed his undergraduate degree at Universidad de Buenos Aires and obtained an MBA from Universidad del CEMA.
Patricio E. Massera active positions
Companies | Position | Start |
---|---|---|
MOLMED S.P.A. | Chief Executive Officer | - |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Chief Executive Officer | 2019-04-30 |
AGC Biologics, Inc.
AGC Biologics, Inc. Pharmaceuticals: OtherHealth Technology AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA. | Chief Executive Officer | 2011-12-31 |
Training of Patricio E. Massera
Universidad de Buenos Aires | Undergraduate Degree |
Universidad del CEMA | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
AGC Biologics SpA
AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
AGC Biologics, Inc.
AGC Biologics, Inc. Pharmaceuticals: OtherHealth Technology AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Patricio E. Massera